BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1472 related articles for article (PubMed ID: 16441426)

  • 1. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
    Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
    Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising allo-restricted cytotoxic T lymphocytes by co-culture of murine splenocytes with autologous macrophage bearing the peptide/allo-major histococompatibility complex.
    Chen X; Yan Y; Lu S; Weng X; Liang Z; Li J; Zhong M; Tang J; Xiao W; Sun W; Shen G; Wu X
    Hum Immunol; 2009 Feb; 70(2):79-84. PubMed ID: 19100802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition.
    Dillon SR; Jameson SC; Fink PJ
    J Immunol; 1994 Feb; 152(4):1790-801. PubMed ID: 8120388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
    Ma H; Kapp JA
    Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
    Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
    J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice.
    Auphan N; Curnow J; Guimezanes A; Langlet C; Malissen B; Mellor A; Schmitt-Verhulst AM
    Eur J Immunol; 1994 Jul; 24(7):1572-7. PubMed ID: 8026519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide.
    Heeg K; Kuon W; Wagner H
    Eur J Immunol; 1991 Jun; 21(6):1523-7. PubMed ID: 1904363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
    Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
    J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant.
    Nikolić-Zugić J; Carbone FR
    Eur J Immunol; 1990 Nov; 20(11):2431-7. PubMed ID: 2253683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
    Kuhröber A; Schirmbeck R; Reimann J
    Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-dependent variation of major histocompatibility complex (MHC) restriction and expression of Ly-2 and CD3/alpha/beta T cell receptor in cloned cytotoxic T cells.
    Weltzien HU; Kempkes B; Studer R; Melchers I; Eichmann K
    Eur J Immunol; 1988 Mar; 18(3):431-7. PubMed ID: 2965649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of H-2K(b)-restricted T-cell epitopes within the nucleocapsid protein of Hantaan virus and establishment of cytotoxic T-cell clones.
    Park JM; Cho SY; Hwang YK; Um SH; Kim WJ; Cheong HS; Byun SM
    J Med Virol; 2000 Feb; 60(2):189-99. PubMed ID: 10596020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low binding capacity of murine tetramers mutated at residue 227 does not preclude the ability to efficiently activate CD8+ T lymphocytes.
    Nugent CT; Renteria RO; Kuus-Reichel K; Kumar A
    Immunol Lett; 2005 May; 98(2):208-15. PubMed ID: 15860220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
    Tremblay N; Fontaine P; Perreault C
    Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
    Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
    Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
    Wang W; Golding B
    Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.